Ibrutinib-associated Arthralgias/Myalgias in Patients with Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes

Ibrutinib-associated arthralgias/myalgias are a frequent adverse event which can occur late in the treatment course and are mostly Grade 1 or 2. For patients with Grade 1 or 2 arthralgias/myalgias, dose reductions can frequently mitigate the side effects and allow patients to continue on therapy, while the majority of patients with Grade 3 toxicity ultimately discontinue therapy. Further study is needed to determine their pathogenesis in order to develop best practice management strategies.

Source: Clinical Lymphoma, Myeloma and Leukemia - February 25, 2020 Category: Hematology Authors: Joanna M. Rhodes, Vincent LoRe, Anthony R. Mato, Elise A. Chong, Jacqueline C. Barrientos, James N. Gerson, Stefan K. Barta, Daniel J. Landsburg, Sunita Dwivedy Nasta, Jakub Svoboda, Alison W. Loren, Stephen J. Schuster Tags: Original Study Source Type: research